Of note, a large proportion of HLA class I negative endometrial cancers are MSI [14], therefore, separate analysis of MSI and MSS tumors would be of interest to determine the prognostic impact of HLA class I. This study indirectly showed no effect of HLA class I expression on survival via the JAK1 mutation status in a large cohort of MSI, early-stage endometrial cancers. This evidence concerns the gene JAK1 and endometrial cancer.